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The ultimate goal of vaccine development is licensure of a safe and efﬁcacious product that has a well-
deﬁned manufacturing process resulting in a high quality product. In general, clinical development and
regulatory approval occurs in a linear, sequential manner: Phase 1 e safety, immunogenicity; Phase 2 e
immunogenicity, safety, dose ranging and preliminary efﬁcacy; Phase 3 e deﬁnitive efﬁcacy, safety, lot
consistency; and, following regulatory approval, Phase 4 e post-marketing safety and effectiveness. For
candidate TB vaccines, where correlates of protection are not yet identiﬁed, phase 2 and 3 efﬁcacy of
disease prevention trials are, by necessity, very large. Each trial would span 2e5 years, with full licensure
expected only after 1 or even 2 decades of development. Given the urgent unmet need for a new TB
vaccine, a satellite discussion was held at the International African Vaccinology Conference in Cape Town,
South Africa in November 2012, to explore the possibility of expediting licensure by use of an “adaptive
licensure” process, based on a risk/beneﬁt assessment that is speciﬁc to regional needs informed by
epidemiology. This may be appropriate for diseases such as TB, where high rates of morbidity, mortality,
particularly in high disease burden countries, impose an urgent need for disease prevention. The dis-
cussion focused on two contexts: licensure within the South African regulatory environment e a high
burden country where TB vaccine efﬁcacy trials are on-going, and licensure by the United States FDA –a
well-resourced regulatory agency where approval could facilitate global licensure of a novel TB vaccine.
 2013 Published by Elsevier Ltd.1. Background
TB remains a leading cause of morbidity andmortality inmost of
the developing world [1]. The emergence of extensively drug-
resistant TB (XDR-TB) and disease rates that are slow to decline
despite the implementation of TB control programs of varying
effectiveness, in regions where the epidemic hits the hardest, make
a compelling argument for the expeditious introduction of a novel
preventive vaccine [1,2]. The only vaccine currently licensed forn Partnership, South African
ustomjee).
Elsevier Ltd.prevention of TB is BCG, which has variable protective beneﬁt in the
prevention of pulmonary TB, with waning protective beneﬁt over
time and little or no effect on repeat administration [2,3]. The need
for improvement is clear and several new vaccines are under
development [3]. Many important steps are currently underway
that may lead to a novel TB vaccine, but important downstream
requirements are just beginning to be addressed. Among them is
vaccine manufacturing, which will need to be scaled up with sub-
stantial modiﬁcations to formulations and presentations for
administration of the vaccine prior to routine use. Most impor-
tantly there is an expectation that efﬁcacy will be conﬁrmed in
large phase 3 trials, perhaps in different regions [4]. This work may
take years following completion of a successful phase 2 study, even
utilizing an adaptive phase 2/3 trial design, which permits pre-
speciﬁed changes in certain speciﬁc aspects of the conduct of a
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cussed with and agreed to by relevant regulatory authorities [4].
Conventional regulatory pathways could delay vaccine licensure
and utilization for many years, potentially leaving high-risk pop-
ulations vulnerable to on-going pathogen exposure and develop-
ment of disease. In light of this challenge, the concept of “adaptive
licensure” has been invoked in an effort to create a more ﬂexible
and potentially more efﬁcient regulatory pathway to licensure [5].
Adaptive licensure is distinguished from adaptive design [4] as the
former refers to the creation of a new regulatory pathwaywhile the
latter addresses the actual conduct of a speciﬁc clinical trial.
Conceptually, adaptive licensure offers the potential for permitting
early access to new vaccines in speciﬁc countries under careful
regulatory control while providing opportunities for development
of additional information on the safety and efﬁcacy of the vaccine to
permit the future widening of the product’s indication [5,6]. For
example, after a successful phase 2b trial and initiation of conﬁr-
matory clinical trials, an adaptive licensure approach could be used
to allow early, limited licensure of a vaccine. This limited licensure
would be conditional on subsequent submission of ﬁnal data from
these trials. An early approval of this type would:
 Provide access to a novel vaccine for speciﬁc populations, e.g.
adolescents
 Simultaneously allow completion of a more robust phase 3 ef-
ﬁcacy study or an effectiveness study with controlled use in
selected areas with enhanced surveillance
 Include safety data of the vaccine from target populations
closely monitored at an early stage of use
Such a process has not been extensively explored with regula-
tors to date. In addition, a number of critical questions about the
adaptive licensure mechanism need to be addressed, including: [1]
would this approach require implementation of a new regulatory
policy or does the relevant regulatory body already possess the
required authority? [2] How should efﬁcacy, effectiveness and
safety be assessed utilizing an adaptive licensure approach? [3]
What groups should be involved in planning and implementing an
adaptive licensure strategy? [4] While an adaptive licensure pro-
cess might be desirable for high TB disease burden countries such
as South Africa, where efﬁcacy trials are predominantly conducted,
registration by this process could impact licensure in other coun-
tries or regions. These questions and other topics were addressed at
a satellite meeting of stakeholders attending the International Af-
rican Vaccinology Conference in Cape Town, South Africa, in
November 2012 [7]. Discussions focused upon the main challenges
to be considered when considering a novel regulatory strategy,
such as adaptive licensure, for a novel TB vaccine.
2. Application of existing mechanisms for expedited licensure
to vaccines
Several mechanisms have been developed to overcome limita-
tions to accessing investigational products. For example, compas-
sionate use and expanded access programs have long allowed
infrequent pre-licensure use of life-saving medicines [8]. Beyond
compassionate use mechanisms, existing regulatory pathways to
licensure of a new medicine can differ considerably depending on
the urgency of the medical need. When there is a serious unmet
medical need that is potentially treatable with the new medicine,
the development and approval processes may be shortened signif-
icantly by making use of a number of regulatory options existing
within traditional regulatory pathways [8]. At the United States (US)
Food and Drug Administration (FDA), these options include: (i) fast
track designation; (ii) priority review designation, and (iii)breakthrough therapy designation [9,10]. Additionally, the acceler-
ated approval regulations (21 CFR 601 Subpart E for biological
products) permit a vaccine developed to prevent or ameliorate a
serious or life threatening illness, such as TB, to be granted licensure
based on efﬁcacy data from a surrogate endpoint shown to be
reasonably likely to predict clinical beneﬁt [11]. Licensure under the
accelerated approval pathway may be conditional, whereby the
sponsor may be required to conduct post-marketing trials to verify
and describe the drug’s clinical beneﬁt [11]. For neglected tropical
diseases that are not typically endemic to the U.S. such as TB, a US
FDA guidance document also discusses principles for developing
vaccines to protect against global diseases [12,13]. In the European
Union (EU), European Medicines Agency (EMA) regulatory mecha-
nisms include: (i) Conditional Approval; (ii) Exceptional Circum-
stances, and (iii) Accelerated Assessment [14]. In the EU, Conditional
Approval is similar to the accelerated approval regulation used by
the FDA but the circumstances are less speciﬁcally prescribed. Many
regulatory agencies also have mechanisms for providing early
advice on product and clinical plans which is particularly important
for the clinical testing of novel vaccines for global diseases like
TB [13,14].
In addition to these ofﬁcial mechanisms for making important
medicinesmore readily available, the approval process itselfmay also
reﬂect the human element of care and concern. For example, in 1996
the FDA approved one of the ﬁrst protease inhibitors for HIV in just 6
weeks, signiﬁcantly faster than the ofﬁcially mandated timeline for
priority review (6months) and certainlymuch faster than theaverage
approval time [15]. The rapid approval of newdrugs for the treatment
ofAIDScontinues todemonstrate the typeofﬂexibility that regulators
can provide when there is a serious need for expediency [15].
Regulatory schemes that provide needed medicines to the pa-
tient most expeditiously are generally associated with some type of
abbreviated or provisional approval, typically based on phase 2 or
early phase 3 clinical data, using surrogatemarkers or a less rigorous
clinical outcome [16]. The availability of a clinically conﬁrmed sur-
rogate endpoint, the strength of the early clinical data in demon-
strating a positive risk/beneﬁt proﬁle, and the extent to which the
product addresses an unmet medical need are factors often
considered by regulatory agencies in deciding whether a vaccine
may be licensed before conﬁrmatory clinical efﬁcacy trials are
completed [11,13]. This is particularly important when such trials
may take many years to complete or may not be feasible [4e6].
Decisions regarding licensure necessarily include assessments
of the risk/beneﬁt ratio of the product from a national perspective
since, for example, the expedited availability of a vaccine may be
more important to an endemic region than other parts of the world
where the risk of disease is low. Mechanisms to accelerate licensure
of new medicines may be less familiar to those working with vac-
cines than those working with medicines for very sick patients,
such as oncology products [17] and HIV therapeutics [15]. However,
since FDA recently approved bedaquiline [18] for treatment of
MDR-TB on the basis of phase 2 data utilizing the accelerated
approval process, and the EMA is making an assessment under a
similar conditional licensure process for both bedaquiline and
delamanid [18,19], mechanisms to advance product approval and
introduction are already proving to be important to the TB ﬁeld.
There are examples of vaccines where efﬁcacy has proven to be
difﬁcult to demonstrate in controlled clinical trials. These include
meningococcal conjugate vaccines, for which immunogenicity was
considered adequate initially for group C vaccines in the UK [20]
and subsequently for combined group A, C, Y and W135 vaccines
in the United States. The FDA Vaccines and Related Biological
Products Advisory Committee has advised that licensure on the
basis of immunogenicity would sufﬁce for a novel group B
meningococcal vaccine and such data has been used to approve a
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meningococcal disease and demonstrated safety of the meningo-
coccal vaccines played a key role in determining the acceptability of
this approval route [20].
3. Principles of adaptive licensure
There is substantial debate on the concept of adaptive licensure
[15], deﬁned as using a progressive, staged licensure process where
there is a sense of urgency for introducing a product to save lives.
Adaptive Licensing should not be viewed as enabling a less rigorous
product development plan but as requiring closer interaction be-
tween regulators, industry, academia and the general population to
ensure that the process works to the ultimate advantage of those
who receive novel medicines. The process is, in part, predicated on
an “acknowledgement of an acceptable level of uncertainty” [5]. For
example, a novel TB vaccine being evaluated in a phase 2 efﬁcacy
trial will have already demonstrated a reasonable safety and efﬁ-
cacy proﬁle following assessment in phase 1 and early phase 2
studies [4]. However, in the absence of a correlate of protection,
“beneﬁt” can only be assessed in a large and lengthy efﬁcacy trial
based upon clinical endpoints [4]. Accordingly, adaptive licensing of
a TB vaccine may require each relevant regulatory agency to
determine the risk/beneﬁt between the level of uncertain efﬁcacy
of the product and the endemic disease burden acceptable to
permit a conditional licensure under this regulatory approach.
There are many challenges and substantial resistance to adapting
novel licensing strategies. Although adaptive licensure is being dis-
cussed by regulators, there is currently no formal acceptance of this
regulatory pathway among the world’s major regulatory bodies. For
this to be achieved, therewill be a need for all stakeholders to accept
trade-offs and risk. For example, manufacturers may need to accept
that the ﬁrst approvals will initially have a more limited indication
reﬂected in their labeling during a period of expanded clinical eval-
uation. It will be important to clarify whether an adaptive licensure
strategy is feasible under current legislation guiding the major reg-
ulatory agencies. Additionally, it will be important to consider
whetheranadequatemeansexists to assess post-marketingdata and
if there are regulatory resources to implement such an approach.
SinceWHO “prequaliﬁcation”of vaccines is likely to bepursuedbyTB
vaccine developers to enhance global distribution [21], it would be
useful to clarify whether conditional approval through an adaptive
licensure process would qualify for WHO prequaliﬁcation. Approval
may also be granted based on “limited use” and while potentially
easier in certain populations in non-endemic countries; it may be
difﬁcult to deﬁne this population in a TB endemic area. Lastly, if the
introduction of a new TB vaccine includes replacing the BCG vacci-
nation in infants, the new vaccine would need to show non-
inferiority or superiority to the existing BCG vaccine which may
not be feasible in a smaller phase 2 efﬁcacy study [2,3].
4. Statistical requirements for licensure based on a vaccine
efﬁcacy study
In the absence of a validated correlate of protection, licensure of
a TB vaccine would need to be based upon efﬁcacy against a disease
endpoint [2e4]. Since vaccine efﬁcacy from randomized clinical
trials is described by a point estimate and a conﬁdence interval (CI),
a narrow CI around the point estimate increases conﬁdence that the
vaccine efﬁcacy is precise, but requires larger studies. In the US, the
lower bound (LB) of the 95% CI is the preferred criterion for
assessing vaccine efﬁcacy by the FDA, reﬂecting a more conserva-
tive standard than the point estimate. This is important given po-
tential for widespread administration of vaccines to healthy
persons. Within the Center for Biologics Evaluation and Research(CBER) of the US FDA, an internal guide for assessment of vaccine
efﬁcacy suggests that the LB of the 95% CI should be; (i) at least two-
thirds to three-quarters of the point estimate of efﬁcacy (e.g., for a
point estimate of 60%, the LB of the 95% CI should be 40%e45%) and
(ii) substantially above 0. There are situations, however, potentially
relevant to novel TB vaccines, where:
/ lower efﬁcacy estimates may be acceptable for a disease
causing high morbidity/mortality, as well as limited/difﬁcult
therapeutic or preventive alternatives and where public
health considerations support use of a vaccine demon-
strating moderate efﬁcacy;
/ wider CIs may be acceptable if the sample size required to
narrow the CI around the point estimate makes the trial
infeasible (e.g. in situations of relatively low disease inci-
dence, or long duration to reach clinical endpoints);
Could a phase 2 efﬁcacy trial sized to show statistical signiﬁ-
cance with the LB of the 95% CI being only slightly above zero be
adequate for licensure by regulatory agencies like the FDA or the
Medicines Control Council (MCC) of South Africa? Features that
would likely be required for licensure studies include use of pre-
deﬁned endpoints with prior validation of diagnostic methods and
the use of the to-be-marketed product, with lot-to-lot consistency
studies also being conducted.
A critical issue for the ﬁrst registration of a new vaccine,
particularly for global diseases like tuberculosis, is the selection of
efﬁcacy thresholds sufﬁcient for licensure. These thresholds will be
dependent on local public health exigencies. Prudence should
guide against setting a low efﬁcacy threshold to mitigate the risk of
licensing a vaccine with low efﬁcacy creating an unacceptable risk/
beneﬁt situation (harm could outweigh good), thereby eroding
public trust. When selecting an efﬁcacy threshold, it will be
essential to guard against creating unmet expectations, a situation
that could arise if a low efﬁcacy threshold were to be selected and
the use of the vaccine had little to no effect on the public health
problem against which it was targeted. Such a situation could
reduce conﬁdence in regulatory agency assessments or in vaccine
use in general. Assessments of future vaccines may also be
compromised because studies comparing vaccines head to head
can be very large relative to placebo controlled trials, and non-
inferiority designs introduce potential for “creep” toward less
efﬁcacious vaccines, when each subsequent vaccine produced
demonstrates non-inferiority to the lower margin of the efﬁcacy
spectrum. Such a situation could result in high costs to society to
implement and pay for vaccination programs of marginal beneﬁt.
Also, there are potential opportunity costs if licensing of improved
vaccines is delayed. Additional factors that might be considered in
selection of an efﬁcacy threshold for approval include: a) previous
regulatory decisions regarding products of a similar class, or those
addressing similar public health challenges; b) preceding data in
phase 2 studies that support reasonable estimates of efﬁcacy; c)
potential public health impact (e.g., effect on morbidity/mortality);
and d), feasibility issues for designing a sufﬁciently sized study to
demonstrate efﬁcacy with high conﬁdence.
5. Current regulatory pathways for accelerating approval of
important new medicines in South Africa
The challenges of expedited licensure in high disease burden
developing countries where most of the TB vaccine trials are con-
ducted are numerous. In large part, this is because regulatory sys-
tems in such countries are typically less well-resourced and
therefore less developed than those in low disease incidence,
economically-advantaged countries. The South African Regulatory
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with experience in the review and oversight of clinical trials. Under
South African regulation, however, no mandate for conditional or
adaptive registration of medicines exists. To allow for use of an
unregistered medicine in the country, a mechanism under Section
21 of Act 101 is available. An applicant applies for, and the Council
may authorize, the sale of a speciﬁc quantity of unregistered
medicine to particular individuals for up to six months (for each
authorization) [22]. This mechanism is also available for medicinal
products in clinical development for which data on product
manufacturing quality are available. Therefore Section 21 approvals
allow for the off-label sale and use of investigational products and
require that the details of every person treated are recorded, and
that such data, including adverse reaction data, is directly reported
to the Registrar of Medicines. However, this reporting process is
unlikely to be applied as rigorously and monitored as thoroughly as
would be required for adaptive licensing, especially for a widely-
used vaccine. Therefore an adaptive licensure process, as
currently being explored, is very difﬁcult to envisage in the current
South Africa context. Furthermore, the MCC, like most regulatory
agencies, is unaccustomed to registering vaccines that have mod-
erate levels of efﬁcacy (VEw 50%), which maywell be the case for a
TB vaccine. Unless indirect/economic beneﬁts (hospitalization,
treatment cost savings, deaths averted) are explicitly elucidated,
the MCC ordinarily considers risk-beneﬁt to the individual rather
than primarily public health considerations. For vaccines of lower
efﬁcacy, the safety/reactogenicity issues become more important,
and consequently, risk-beneﬁt must be very clearly demonstrated.
Given these considerations, the prospects for adaptive licensure
in South Africa will be limited, particularly as long as Section 21 ap-
provals remain the sole mechanism. Currently under discussion by
theMCC is a proposed InvestigationalMedicinal Product Application
(IMPA) procedure for South Africa allowing for pre-registration
consultations with a technical expert committee of the MCC [23].
The intention is to provide a mechanism for interaction between
product developers and the MCC that will guide product develop-
ment and facility design, and facilitate compliance with the regula-
tions governing the registration of medicines for use in the country.
Use of this mechanism would be limited to biological and other
medicines thathavenot beenpreviously submitted for registration to
the MCC or to any other regulatory authority and for which regis-
tration may be sought from the MCC in the future. The IMPAwould,
therefore, be accessible to local manufacturers and developers of
biological medicines, including vaccine developers, where themajor
part of the clinical developmentwill be in a SouthAfricanpopulation.
Initiatives in other regulatory settings for discussion of product
development strategies, novel regulatory mechanisms and poten-
tial harmonization across regulatory agencies for the registration of
TB vaccines, include the pre-IND consultation procedure of the FDA
[24], the Scientiﬁc Advice and Protocol Assistance procedures of the
EMA [25] (which are also applicable for products to be assessed
under EMA article 58 of regulation 726/2004 [26]), the Developing
Countries’ Vaccine Regulators Network (DCVRN) [27], the African
Vaccine Regulators Forum (AVAREF) [28] and the Health Canada
Progressive Licensing Project [29]. These regulatory initiatives offer
sponsors of novel TB vaccines a number of advantages, including
opportunities for discussions on developing a licensing plan and
opening dialogue amongst sponsors, developers, regulators and
health authorities, and the chance tomake a plea for harmonization
among these different stakeholders [21].
A number of challenges have resulted from this discussion on
adaptive licensure and the role of regulatory authorities in expediting
the review and introduction of vaccines for TB. Overcoming these
challenges will require innovative strategic plans that address regu-
latory challenges in both emerging countries like South Africa andnationswith stringent regulatory agencies (SRA) like the US. Thiswill
be particularly difﬁcult for eventually implementing “non-tradi-
tional” approaches such as adaptive licensure. As discussed in this
article, one strategy is to use the resources of a stringent regulatory
authority such as the US FDA toworkwith regulatoryagencies (RA) in
countries endemic for global diseases like the MCC in South Africa to
complement the strengths of both agencies in assessing the data
associated with the regulatory submission including the clinical trial
data and the proposed plans for conditional approval. Strategies for
fostering communication and collaborations among SRAs and RAs
have been documented in a number of publications focused on in-
formation sharing among regulatory bodies and strengthening the
capacity of less well-resourced RAs in developing countries to tackle
the reviewof complex biological vaccine products under a reasonable
timeframe. Moran et al., for example, focuses on the training and
exchange of information between SRAs and RAs, called “twinned-
review” [30], while Maiga et al. comments on the importance of the
World Health Organization initiatives like the African Vaccine Regu-
latory Forum in harmonizing the regulation of vaccines in Africa [31].
The AVAREF has reviewed an adaptive trial protocol for TB vaccines
and a summaryof their comments is published inRustomjee et al. [4].
In addition, a series of reports by the Global Health Technologies
Coalition which represents non-proﬁts and product development
partnerships developing products for neglected diseases provides a
number of recommendations on howUS policy could bolster the role
of the US FDA in global health [32] Also, a report by the Centers for
Global Development [33] recommends a two e prong approach to
streamlining the introduction of products for neglected diseases
focusing on changes to clinical development and harmonization of
regional regulatorypathways. Aspointed out in a review [34], a global
regulatory science agenda which encompasses strengthening of
laboratory-based regulatory science and inclusion of adaptive trial
designs and other less traditional approaches to evaluating vaccines
for global diseases is an important part of the Decade of Vaccines
Collaboration and the Global Vaccine Action plan. Therefore, for the
mostpart, strategies to address theobstacles to thepotential licensure
pathwaysoutlined in this report exist and themain challenge remains
in ﬁnding the resources and political mechanisms for implementing
change within regulatory bodies needed for efﬁcient approval and
introduction of new products for neglected global diseases.
In summary, the potential for expediting licensure of a TB vac-
cine using “Adaptive Licensure” appears challenging, both in South
Africa and the USA. Nonetheless, it is widely accepted that the
critical importance of developing and introducing an improved TB
vaccine should lead all stakeholders to work to establish the most
efﬁcient possible route to licensure for the introduction of a novel
vaccines for tuberculosis.
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